Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020: Workshop Summary, Authors: R M Califf. Background: The conduct of clinical trials should be an integral part of routine patient care. Treating patients in trials incurs additional costs over and above standard of care (SOC), but the extent of the cost burden is not known. We undertook a retrospective cost attribution analysis to quantify the treatment costs associated with cancer clinical trial protocols conducted over a 2 year period. Article. Full-text available. Jan 2020, Stephen Sonstein, Rebecca N Brouwer, William Gluck, Carolynn Thomas Jones. Find many great new & used options and get the best deals for Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020: Workshop Summary by R M Califf, Atlas Health Foundation; Robert M. Califf, Duke University Medical Center; Gary L. Filerman, Atlas Health Foundation; Richard K. Murray, Merck & Co., Inc. This discussion paper was presented in draft form at the Forum's November 2011 workshop, Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020, and finalized by the authors following the workshop. The authors would like to thank David Davis, Jeffrey Drazen, Ronald Kral, Samuel Nussbaum, Neil Weissman, and Marcus Wilson for their comments and suggestions on draft versions of this paper.